📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Correction: A human Myogenin promoter modified to be highly active in alveolar rhabdomyosarcoma drives an effective suicide gene therapy. (2021)

First Author: Pruller J

Attributed to: Understanding and Ameliorating perturbed signalling and pathogenesis in FSHD funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1038/s41417-020-00251-y

PubMed Identifier: 33177625

Publication URI: http://europepmc.org/abstract/MED/33177625

Type: Journal Article/Review

Volume: 28

Parent Publication: Cancer gene therapy

Issue: 5

ISSN: 0929-1903